Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1996 Sep;165(3):131–138.

Predictors of thyroid tumor aggressiveness.

O H Clark 1
PMCID: PMC1303719  PMID: 8909165

Abstract

Thyroid cancers are classified as papillary, follicular (including Hürthle cell), medullary, and anaplastic. Papillary cancers account for about 82% of all thyroid cancers, follicular about 8%, medullary about 6%, Hürthle cell 3%, and anaplastic 1%. The prognosis of patients with papillary thyroid cancer is usually favorable, whereas most patients with anaplastic cancer die within 6 months. The behavior of papillary thyroid cancer can be predicted by patient age, sex, tumor size, local invasion, angioinvasion, lymph node metastases, distant metastases, as well as tumor differentiation and ability to take up radioactive iodine. Thus, older male patients with larger or invasive tumors, with angioinvasion, lymph node or distant metastases, and with tumors that do not take up radioactive iodine or cannot be completely surgically resected have a worse prognosis. Anaploid tumors, tumors with a low adenylate cyclase response to thyroid-stimulating hormone tumors, tumors that are ras-and gsp-positive, and tumors that are p21-positive and p53-positive also appear to behave in a more aggressive manner. In contrast, lymphocytic thyroiditis associated with papillary thyroid cancer predicts fewer recurrences and an improved survival. The treatment of patients with papillary thyroid cancer is controversial primarily because most patients do well with relatively minimal therapy, and there are no prospective studies concerning the merits of various treatments. Much of the controversy relates to the safety of thyroidectomy versus other procedures and, to a lesser extent, when to do a central or modified radical neck dissection. The rate of recurrence is lower, and the death rate may also be lower when patients are treated initially by total thyroidectomy. The rationale for total thyroidectomy is that it enables one to use radioactive iodine to detect and treat local and distant metastases, and it makes serum thyroglobulin determination more sensitive for detecting persistent disease. Total thyroidectomy should be associated with a permanent complication rate of less than 2%. Thyroid-stimulating hormone suppression therapy is recommended by most experts for patients with differentiated thyroid cancer and supported by most clinical and laboratory studies. Central and lateral node selection is recommended for patients with palpable lymphadenopathy.

Full text

PDF
131

Images in this article

133Figure 2.
on p.133

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacourt F., Asselain B., Savoie J. C., D'Hubert E., Massin J. P., Doucet G., Leger A., Garnier H. Multifactorial study of prognostic factors in differentiated thyroid carcinoma and a re-evaluation of the importance of age. Br J Surg. 1986 Apr;73(4):274–277. doi: 10.1002/bjs.1800730410. [DOI] [PubMed] [Google Scholar]
  2. Byar D. P., Green S. B., Dor P., Williams E. D., Colon J., van Gilse H. A., Mayer M., Sylvester R. J., van Glabbeke M. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer. 1979 Aug;15(8):1033–1041. doi: 10.1016/0014-2964(79)90291-3. [DOI] [PubMed] [Google Scholar]
  3. Bäckdahl M., Carstensen J., Auer G., Tallroth E. Statistical evaluation of the prognostic value of nuclear DNA content in papillary, follicular, and medullary thyroid tumors. World J Surg. 1986 Dec;10(6):974–980. doi: 10.1007/BF01658650. [DOI] [PubMed] [Google Scholar]
  4. Cady B., Cohn K., Rossi R. L., Sedgwick C. E., Meissner W. A., Werber J., Gelman R. S. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery. 1983 Dec;94(6):978–983. [PubMed] [Google Scholar]
  5. Cady B., Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988 Dec;104(6):947–953. [PubMed] [Google Scholar]
  6. Cady B., Sedgwick C. E., Meissner W. A., Bookwalter J. R., Romagosa V., Werber J. Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg. 1976 Nov;184(5):541–553. doi: 10.1097/00000658-197611000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Casara D., Rubello D., Saladini G., Masarotto G., Favero A., Girelli M. E., Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 1993 Oct;34(10):1626–1631. [PubMed] [Google Scholar]
  8. Clark O. H., Gerend P. L. Thyrotropin receptor-adenylate cyclase system in Hurthle cell neoplasms. J Clin Endocrinol Metab. 1985 Oct;61(4):773–778. doi: 10.1210/jcem-61-4-773. [DOI] [PubMed] [Google Scholar]
  9. Clark O. H., Hoelting T. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid. 1994 Winter;4(4):501–505. doi: 10.1089/thy.1994.4.501. [DOI] [PubMed] [Google Scholar]
  10. Crile G., Jr A second opinion about thyroid hormone treatment. Surgery. 1988 Feb;103(2):268–269. [PubMed] [Google Scholar]
  11. DeGroot L. J., Kaplan E. L., McCormick M., Straus F. H. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990 Aug;71(2):414–424. doi: 10.1210/jcem-71-2-414. [DOI] [PubMed] [Google Scholar]
  12. Demeter J. G., De Jong S. A., Lawrence A. M., Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery. 1991 Dec;110(6):956–963. [PubMed] [Google Scholar]
  13. Donghi R., Sozzi G., Pierotti M. A., Biunno I., Miozzo M., Fusco A., Grieco M., Santoro M., Vecchio G., Spurr N. K. The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). Oncogene. 1989 Apr;4(4):521–523. [PubMed] [Google Scholar]
  14. Duh Q. Y., Gum E. T., Gerend P. L., Raper S. E., Clark O. H. Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery. 1985 Dec;98(6):1000–1007. [PubMed] [Google Scholar]
  15. Emerick G. T., Duh Q. Y., Siperstein A. E., Burrow G. N., Clark O. H. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer. 1993 Dec 1;72(11):3287–3295. doi: 10.1002/1097-0142(19931201)72:11<3287::aid-cncr2820721126>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  16. Fagin J. A., Matsuo K., Karmakar A., Chen D. L., Tang S. H., Koeffler H. P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 1993 Jan;91(1):179–184. doi: 10.1172/JCI116168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fusco A., Grieco M., Santoro M., Berlingieri M. T., Pilotti S., Pierotti M. A., Della Porta G., Vecchio G. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature. 1987 Jul 9;328(6126):170–172. doi: 10.1038/328170a0. [DOI] [PubMed] [Google Scholar]
  18. Goretzki P. E., Lyons J., Stacy-Phipps S., Rosenau W., Demeure M., Clark O. H., McCormick F., Röher H. D., Bourne H. R. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg. 1992 Jul-Aug;16(4):576–582. doi: 10.1007/BF02067325. [DOI] [PubMed] [Google Scholar]
  19. Harness J. K., Thompson N. W., McLeod M. K., Pasieka J. L., Fukuuchi A. Differentiated thyroid carcinoma in children and adolescents. World J Surg. 1992 Jul-Aug;16(4):547–554. doi: 10.1007/BF02067317. [DOI] [PubMed] [Google Scholar]
  20. Harness J. K., Thompson N. W., Nishiyama R. H. Childhood thyroid carcinoma. Arch Surg. 1971 Apr;102(4):278–284. doi: 10.1001/archsurg.1971.01350040040008. [DOI] [PubMed] [Google Scholar]
  21. Harwood J., Clark O. H., Dunphy J. E. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg. 1978 Jul;136(1):107–112. doi: 10.1016/0002-9610(78)90209-x. [DOI] [PubMed] [Google Scholar]
  22. Hay I. D., Bergstralh E. J., Goellner J. R., Ebersold J. R., Grant C. S. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993 Dec;114(6):1050–1058. [PubMed] [Google Scholar]
  23. Hay I. D., Grant C. S., Taylor W. F., McConahey W. M. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987 Dec;102(6):1088–1095. [PubMed] [Google Scholar]
  24. Hay I. D. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990 Sep;19(3):545–576. [PubMed] [Google Scholar]
  25. Hutter R. V., Frazell E. L., Foote F. W., Jr Elective radical neck dissection: an assessment of its use in the management of papillary thyroid cancer. CA Cancer J Clin. 1970 Mar-Apr;20(2):87–93. [PubMed] [Google Scholar]
  26. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y., Dohi K., Nakamura N., Akiyama M. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992 Mar 1;52(5):1369–1371. [PubMed] [Google Scholar]
  27. Joensuu H., Klemi P., Eerola E., Tuominen J. Influence of cellular DNA content on survival in differentiated thyroid cancer. Cancer. 1986 Dec 1;58(11):2462–2467. doi: 10.1002/1097-0142(19861201)58:11<2462::aid-cncr2820581119>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  28. Johnson T. L., Lloyd R. V., Thor A. Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues. Am J Pathol. 1987 Apr;127(1):60–65. [PMC free article] [PubMed] [Google Scholar]
  29. La Quaglia M. P., Corbally M. T., Heller G., Exelby P. R., Brennan M. F. Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery. 1988 Dec;104(6):1149–1156. [PubMed] [Google Scholar]
  30. Leeper R. D. The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab. 1973 Jun;36(6):1143–1152. doi: 10.1210/jcem-36-6-1143. [DOI] [PubMed] [Google Scholar]
  31. Lemoine N. R., Mayall E. S., Wyllie F. S., Williams E. D., Goyns M., Stringer B., Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 1989 Feb;4(2):159–164. [PubMed] [Google Scholar]
  32. Lyons J., Landis C. A., Harsh G., Vallar L., Grünewald K., Feichtinger H., Duh Q. Y., Clark O. H., Kawasaki E., Bourne H. R. Two G protein oncogenes in human endocrine tumors. Science. 1990 Aug 10;249(4969):655–659. doi: 10.1126/science.2116665. [DOI] [PubMed] [Google Scholar]
  33. Massin J. P., Savoie J. C., Garnier H., Guiraudon G., Leger F. A., Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer. 1984 Feb 15;53(4):982–992. doi: 10.1002/1097-0142(19840215)53:4<982::aid-cncr2820530427>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  34. Maxon H. R., 3rd, Smith H. S. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990 Sep;19(3):685–718. [PubMed] [Google Scholar]
  35. Mazzaferri E. L. Papillary and follicular thyroid cancer: a selective approach to diagnosis and treatment. Annu Rev Med. 1981;32:73–91. doi: 10.1146/annurev.me.32.020181.000445. [DOI] [PubMed] [Google Scholar]
  36. Mazzaferri E. L. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol. 1987 Sep;14(3):315–332. [PubMed] [Google Scholar]
  37. Mazzaferri E. L., Young R. L. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981 Mar;70(3):511–518. doi: 10.1016/0002-9343(81)90573-8. [DOI] [PubMed] [Google Scholar]
  38. McConahey W. M., Hay I. D., Woolner L. B., van Heerden J. A., Taylor W. F. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986 Dec;61(12):978–996. doi: 10.1016/s0025-6196(12)62641-x. [DOI] [PubMed] [Google Scholar]
  39. Noguchi S., Noguchi A., Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer. 1970 Nov;26(5):1053–1060. doi: 10.1002/1097-0142(197011)26:5<1053::aid-cncr2820260513>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  40. Noguchi S., Noguchi A., Murakami N. Papillary carcinoma of the thyroid. II. Value of prophylactic lymph node excision. Cancer. 1970 Nov;26(5):1061–1064. doi: 10.1002/1097-0142(197011)26:5<1061::aid-cncr2820260514>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  41. O'Sullivan C., Barton C. M., Staddon S. L., Brown C. L., Lemoine N. R. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog. 1991;4(5):345–349. doi: 10.1002/mc.2940040503. [DOI] [PubMed] [Google Scholar]
  42. Pacini F., Cetani F., Miccoli P., Mancusi F., Ceccarelli C., Lippi F., Martino E., Pinchera A. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994 Jul-Aug;18(4):600–604. doi: 10.1007/BF00353775. [DOI] [PubMed] [Google Scholar]
  43. Pacini F., Pinchera A., Giani C., Grasso L., Baschieri L. Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxf) 1980 Jul;13(1):107–110. doi: 10.1111/j.1365-2265.1980.tb01030.x. [DOI] [PubMed] [Google Scholar]
  44. Pasieka J. L., Thompson N. W., McLeod M. K., Burney R. E., Macha M. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg. 1992 Jul-Aug;16(4):711–717. doi: 10.1007/BF02067365. [DOI] [PubMed] [Google Scholar]
  45. Pineda J. D., Lee T., Ain K., Reynolds J. C., Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995 May;80(5):1488–1492. doi: 10.1210/jcem.80.5.7744991. [DOI] [PubMed] [Google Scholar]
  46. Robbins J., Merino M. J., Boice J. D., Jr, Ron E., Ain K. B., Alexander H. R., Norton J. A., Reynolds J. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med. 1991 Jul 15;115(2):133–147. doi: 10.7326/0003-4819-115-2-133. [DOI] [PubMed] [Google Scholar]
  47. Russell M. A., Gilbert E. F., Jaeschke W. F. Prognostic features of thyroid cancer. A long-term followup of 68 cases. Cancer. 1975 Aug;36(2):553–559. doi: 10.1002/1097-0142(197508)36:2<553::aid-cncr2820360234>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  48. Sakamoto A., Kasai N., Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983 Nov 15;52(10):1849–1855. doi: 10.1002/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  49. Schelfhout L. J., Creutzberg C. L., Hamming J. F., Fleuren G. J., Smeenk D., Hermans J., van de Velde C. J., Goslings B. M. Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur J Cancer Clin Oncol. 1988 Feb;24(2):331–337. doi: 10.1016/0277-5379(88)90276-3. [DOI] [PubMed] [Google Scholar]
  50. Scheumann G. F., Gimm O., Wegener G., Hundeshagen H., Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994 Jul-Aug;18(4):559–568. doi: 10.1007/BF00353765. [DOI] [PubMed] [Google Scholar]
  51. Schlumberger M., Arcangioli O., Piekarski J. D., Tubiana M., Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med. 1988 Nov;29(11):1790–1794. [PubMed] [Google Scholar]
  52. Schlumberger M., Tubiana M., De Vathaire F., Hill C., Gardet P., Travagli J. P., Fragu P., Lumbroso J., Caillou B., Parmentier C. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986 Oct;63(4):960–967. doi: 10.1210/jcem-63-4-960. [DOI] [PubMed] [Google Scholar]
  53. Schröder S., Dralle H., Rehpenning W., Böcker W. Prognosekriterien des papillären Schilddrüsencarcinomas. Morphologisch-klinische Analyse von 202 Tumorfällen. Langenbecks Arch Chir. 1987;371(4):263–280. doi: 10.1007/BF01258974. [DOI] [PubMed] [Google Scholar]
  54. Shah J. P., Medina J. E., Shaha A. R., Schantz S. P., Marti J. R. Cervical lymph node metastasis. Curr Probl Surg. 1993 Mar;30(3):1–335. doi: 10.1016/0011-3840(93)90012-6. [DOI] [PubMed] [Google Scholar]
  55. Siperstein A. E., Zeng Q. H., Gum E. T., Levin K. E., Clark O. H. Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J Surg. 1988 Aug;12(4):528–533. doi: 10.1007/BF01655441. [DOI] [PubMed] [Google Scholar]
  56. Smith S. A., Hay I. D., Goellner J. R., Ryan J. J., McConahey W. M. Mortality from papillary thyroid carcinoma. A case-control study of 56 lethal cases. Cancer. 1988 Oct 1;62(7):1381–1388. doi: 10.1002/1097-0142(19881001)62:7<1381::aid-cncr2820620724>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  57. Solomon B. L., Wartofsky L., Burman K. D. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996 Jan;81(1):333–339. doi: 10.1210/jcem.81.1.8550774. [DOI] [PubMed] [Google Scholar]
  58. Spires J. R., Robbins K. T., Luna M. A., Byers R. M. Metastatic papillary carcinoma of the thyroid: the significance of extranodal extension. Head Neck. 1989 May-Jun;11(3):242–246. doi: 10.1002/hed.2880110309. [DOI] [PubMed] [Google Scholar]
  59. Suarez H. G., du Villard J. A., Caillou B., Schlumberger M., Parmentier C., Monier R. gsp mutations in human thyroid tumours. Oncogene. 1991 Apr;6(4):677–679. [PubMed] [Google Scholar]
  60. Tennvall J., Biörklund A., Möller T., Ranstam J., Akerman M. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up. Cancer. 1986 Apr 1;57(7):1405–1414. doi: 10.1002/1097-0142(19860401)57:7<1405::aid-cncr2820570728>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  61. Tubiana M., Schlumberger M., Rougier P., Laplanche A., Benhamou E., Gardet P., Caillou B., Travagli J. P., Parmentier C. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985 Feb 15;55(4):794–804. doi: 10.1002/1097-0142(19850215)55:4<794::aid-cncr2820550418>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  62. Wilson S. M., Bock G. E. Carcinoma of the thyroid metastatic to lymph nodes of the neck. Arch Surg. 1971 Apr;102(4):285–291. doi: 10.1001/archsurg.1971.01350040047009. [DOI] [PubMed] [Google Scholar]
  63. Witt T. R., Meng R. L., Economou S. G., Southwick H. W. The approach to the irradiated thyroid. Surg Clin North Am. 1979 Feb;59(1):45–63. doi: 10.1016/s0039-6109(16)41732-9. [DOI] [PubMed] [Google Scholar]
  64. Wong J. B., Kaplan M. M., Meyer K. B., Pauker S. G. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am. 1990 Sep;19(3):741–760. [PubMed] [Google Scholar]
  65. Wright P. A., Lemoine N. R., Goretzki P. E., Wyllie F. S., Bond J., Hughes C., Röher H. D., Williams E. D., Wynford-Thomas D. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene. 1991 Sep;6(9):1693–1697. [PubMed] [Google Scholar]
  66. Wright P. A., Williams E. D., Lemoine N. R., Wynford-Thomas D. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene. 1991 Mar;6(3):471–473. [PubMed] [Google Scholar]
  67. Zou M., Shi Y., Farid N. R. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab. 1993 Oct;77(4):1054–1058. doi: 10.1210/jcem.77.4.8408453. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES